A version of this story originally appeared in The Readout, STAT’s biotech newsletter. Sign up here.

D

r. David Hung has had a distinguished career in biotech, presiding over the development of a blockbuster cancer drug and flipping a company for $14 billion. But the last act, in which he led an Alzheimer’s disease startup through a catastrophic failure, is one from which he’d like to move on.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • NELO data will be spectacular
    Its from the ARNA labs
    GPCR technology is 3 for 3 all best in class
    Ralenepig
    Entresimod
    Belviq
    Soon Apd 371 Non opioid pain Non addictive

    He left too soon

  • Jumping on Axovant ship he proved that the first time around he got either unbelievably lucky, or he was just a street smart. Either way, he must be a mediocre scientist/physician.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.